Anti-fibrotic treatments for chronic liver diseases: The present and the future

키워드

참고문헌 (134)

1. Asrani SK, "Burden of liver diseases in the world", J Hepatol, 70, pp.151~171 (2019)
2. European Association for the Study of the Liver, "EASL clinical practice guidelines for the management of patients with decompensated cirrhosis", J Hepatol, 69, pp.406~460 (2018)
3. Zhou WC, "Pathogenesis of liver cirrhosis", World J Gastroenterol, 20, pp.7312~7324 (2014)
4. Pimpin L, "Burden of liver disease in Europe : epidemiology and analysis of risk factors to identify prevention policies", J Hepatol, 69, pp.718~735 (2018)
5. Iredale JP, "Models of liver fibrosis : exploring the dynamic nature of inflammation and repair in a solid organ", J Clin Invest, 117, pp.539~548 (2007)
6. Friedman SL, "Mechanisms of hepatic fibrogenesis", Gastroenterology, 134, pp.1655~1669 (2008)
7. Tsuchida T, "Mechanisms of hepatic stellate cell activation", Nat Rev Gastroenterol Hepatol, 14, pp.397~411 (2017)
8. Wynn TA, "Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases", J Clin Invest, 117, pp.524~529 (2007)
9. Geervliet E, "Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases", Cells, 9, pp.1212~ (2020)
10. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label followup study", Lancet, 381, pp.468~475 (2013)
11. Chang TT, "Longterm entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
12. D’Ambrosio R, "A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis", Hepatology, 56, pp.532~543 (2012)
13. Vilar-Gomez E, "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis", Gastroenterology, 149, pp.367~378.e5 (2015)
14. Maher JJ, "Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer", J Clin Invest, 82, pp.450~459 (1988)
15. Kawada N, "Eicosanoid-mediated contractility of hepatic stellate cells", Biochem J, 285, pp.367~371 (1992)
16. Pinzani M, "Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients", J Clin Invest, 90, pp.642~646 (1992)
17. Koyama Y, "Liver inflammation and fibrosis", J Clin Invest, 127, pp.55~64 (2017)
18. Seki E, "TLR4 enhances TGF-beta signaling and hepatic fibrosis", Nat Med, 13, pp.1324~1332 (2007)
19. Liu C, "Transcriptional repression of the transforming growth factor β(TGF-β)pseudoreceptor BMP and activin membrane-bound inhibitor(BAMBI)by nuclear factor κB(NF-κB)p50 enhances TGF-β signaling in hepatic stellate cells", J Biol Chem, 289, pp.7082~7091 (2014)
20. Yang L, "Regulation of peroxisome proliferator-activated receptorgamma in liver fibrosis", Am J Physiol Gastrointest Liver Physiol, 291, pp.G902~G911 (2006)
21. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
22. Musso G, "Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis : a metaanalysis", JAMA Intern Med, 177, pp.633~640 (2017)
23. Staels B, "Hepatoprotective effects of the dual peroxisome proliferatoractivated receptor alpha", delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease, Hepatology, pp.2013, 58[DOI]
24. Ratziu V, "Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening", Gastroenterology, 150, pp.1147~1159.e5 (2016)
25. "GENFIT: announces results from interim analysis of RESOLVE-IT Phase 3 trial of elafibranor in adults with NASH and fibrosis"[URL]
26. Rotman Y, "Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease", Gut, 66, pp.180~190 (2017)
27. Mann J, "Transcriptional regulation of hepatic stellate cells", Adv Drug Deliv Rev, 61, pp.497~512 (2009)
28. Mudaliar S, "Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease", Gastroenterology, 145, pp.574~582.e1 (2013)
29. Younossi ZM, "Obeticholic acid for the treatment of non-alcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
30. "Intercept receives complete response letter from FDA for obeticholic acid for the treatment of fibrosis due to NASH"[URL]
31. Nishikawa K, "Wnt", β-catenin signaling as a potential target for the treatment of liver cirrhosis using antifibrotic drugs, 2018, pp.19, 3103~
32. Tokunaga Y, "Selective inhibitor of Wnt", β-catenin, Sci Rep, pp.2017, 7[DOI]
33. Kimura K, "Safety, tolerability, and preliminary efficacy of the anti-fibrotic small molecule PRI-724, a CBP", β-catenin inhibitor, in patients with hepatitis C virus-related cirrhosis : a single-center, open-label, dose escalation phase 1 trial, 2017, pp.23, 79~87
34. Schuppan D, "Determinants of fibrosis progression and regression in NASH", J Hepatol, 68, pp.238~250 (2018)
35. Altenhöfer S, "The NOX toolbox : validating the role of NADPH oxidases in physiology and disease", Cell Mol Life Sci, 69, pp.2327~2343 (2012)
36. Drummond GR, "Combating oxidative stress in vascular disease : NADPH oxidases as therapeutic targets", Nat Rev Drug Discov, 10, pp.453~471 (2011)
37. Jiang JX, "Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4", NOX1 inhibitor in vivo, 2012, pp.53, 289~296
38. Paik YH, "The nicotinamide adenine dinucleotide phosphate oxidase(NOX)homologues NOX1 and NOX2", gp91(phox)mediate hepatic fibrosis in mice, 2011, pp.53, 1730~1741
39. Aoyama T, "Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis : GKT137831 as a novel potential therapeutic agent", Hepatology, 56, pp.2316~2327 (2012)
40. Rossignol JF, "Nitazoxanide : a first-in-class broad-spectrum antiviral agent", Antiviral Res, 110, pp.94~103 (2014)
41. Belanger C, "Drug repurposing screen identifies novel small molecule compounds with potent antifibrotic properties", J Hepatol, 66, pp.S605~ (2017)
42. Walczak R, "Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model", J Hepatol, 68, pp.S352~S353 (2018)
43. Burmester T, "Cytoglobin : a novel globin type ubiquitously expressed in vertebrate tissues", Mol Biol Evol, 19, pp.416~421 (2002)
44. Kawada N, "Characterization of a stellate cell activation-associated protein(STAP)with peroxidase activity found in rat hepatic stellate cells", J Biol Chem, 276, pp.25318~25323 (2001)
45. Le Thi Thanh Thuy, "Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis", Clinical and Molecular Hepatology, 26(3), pp.280~293 (2020), 대한간학회[DOI]
46. Okina Y, "TGF-β1-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis", J Hepatol, 73, pp.882~895 (2020)
47. Thuy le TT, "Promotion of liver and lung tumorigenesis in DEN-treated cytoglobin-deficient mice", Am J Pathol, 179, pp.1050~1060 (2011)
48. Li Z, "The effect of rhCygb on CCl4-induced hepatic fibrogenesis in rat", Sci Rep, 6, pp.23508~ (2016)
49. Sato-Matsubara M, "Fibroblast growth factor 2(FGF2)regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling", J Biol Chem, 292, pp.18961~18972 (2017)
50. Issa R, "Apoptosis of hepatic stellate cells : involvement in resolution of biliary fibrosis and regulation by soluble growth factors", Gut, 48, pp.548~557 (2001)
51. Watson MR, "NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts", J Hepatol, 48, pp.589~597 (2008)
52. Zhang Y, "Vitamin Acoupled liposomes carrying TLR4-silencing shRNA induce apoptosis of pancreatic stellate cells and resolution of pancreatic fibrosis", J Mol Med(Berl), 96, pp.445~458 (2018)
53. Ezhilarasan D, "Hepatic fibrosis : it is time to go with hepatic stellate cell-specific therapeutic targets", Hepatobiliary Pancreat Dis Int, 17, pp.192~197 (2018)
54. Barry-Hamilton V, "Allosteric inhibition of lysyl oxidase-like-2impedes the development of a pathologic microenvironment", Nat Med, 16, pp.1009~1017 (2010)
55. Liu SB, "Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice", FASEB J, 30, pp.1599~1609 (2016)
56. Rodriguez HM, "Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor", J Biol Chem, 285, pp.20964~20974 (2010)
57. Harrison SA, "Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis", Gastroenterology, 155, pp.1140~1153 (2018)
58. Muir AJ, "Simtuzumab for primary sclerosing cholangitis : phase 2 study results with insights on the natural history of the disease", Hepatology, 69, pp.684~698 (2019)
59. Karsdal MA, "The good and the bad collagens of fibrosis-their role in signaling and organ function", Adv Drug Deliv Rev, 121, pp.43~56 (2017)
60. Jiménez Calvente C, "Specific hepatic delivery of procollagen α1(I)small interfering RNA in lipid-like nanoparticles resolves liver fibrosis", Hepatology, 62, pp.1285~1297 (2015)
61. Molokanova O, "Inducible knockdown of procollagen I protects mice from liver fibrosis and leads to dysregulated matrix genes and attenuated inflammation", Matrix Biol, 66, pp.34~49 (2018)
62. Tasab M, "Hsp47 : a molecular chaperone that interacts with and stabilizes correctly-folded procollagen", EMBO J, 19, pp.2204~2211 (2000)
63. Ito S, "Biology of Hsp47(Serpin H1), a collagen-specific molecular chaperone", Semin Cell Dev Biol, 62, pp.142~151 (2017)
64. Sato Y, "Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone", Nat Biotechnol, 26, pp.431~442 (2008)
65. Lawitz E, "Safety, pharmacokinetics, and biologic activity of ND-L02-s0201, a novel targeted lipid-nanoparticle to deliver HSP47 siRNA for the treatment of patients with advanced liver fibrosis : interim results from clinical phase 1b", 2 studies, 2015, pp.62, 909A~
66. Schwabe RF, "Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration", Am J Physiol Gastrointest Liver Physiol, 285, pp.G949~G958 (2003)
67. Seki E, "CCR1 and CCR5 promote hepatic fibrosis in mice", J Clin Invest, 119, pp.1858~1870 (2009)
68. Seki E, "CCR2 promotes hepatic fibrosis in mice", Hepatology, 50, pp.185~197 (2009)
69. Mitchell C, "Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice", Am J Pathol, 174, pp.1766~1775 (2009)
70. Berres ML, "Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice", J Clin Invest, 120, pp.4129~4140 (2010)
71. Karlmark KR, "Hepatic recruitment of the inflammatory Gr1+monocyte subset upon liver injury promotes hepatic fibrosis", Hepatology, 50, pp.261~274 (2009)
72. Miura K, "Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2", Am J Physiol Gastrointest Liver Physiol, 302, pp.G1310~G1321 (2012)
73. Pradere JP, "Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice", Hepatology, 58, pp.1461~1473 (2013)
74. Lefebvre E, "Antifibrotic effects of the dual CCR2", CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis, 2016, pp.11, e0158156~
75. Mossanen JC, "Chemokine(C-C motif)receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury", Hepatology, 64, pp.1667~1682 (2016)
76. Friedman SL, "A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis", Hepatology, 67, pp.1754~1767 (2018)
77. Pedrosa M, "A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis : study design of the TANDEM trial", Contemp Clin Trials, 88, pp.105889~ (2020)
78. Yang RY, "Expression of galectin-3 modulates T-cell growth and apoptosis", Proc Natl Acad Sci U S A, 93, pp.6737~6742 (1996)
79. Jeng KC, "An endogenous lectin, galectin-3(epsilon BP", Mac-2), potentiates IL-1 production by human monocytes, 1994, pp.42, 113~116
80. Sano H, "Human galectin-3 is a novel chemoattractant for monocytes and macrophages", J Immunol, 165, pp.2156~2164 (2000)
81. Traber PG, "Therapy of experimental NASH and fibrosis with galectin inhibitors", PLoS One, 8, pp.e83481~ (2013)
82. Traber PG, "Regression of fibrosis and reversal of cirrhosis in rats by galec tin inhibitors in thioacetamide-induced liver disease", PLoS One, 8, pp.e75361~ (2013)
83. Chalasani N, "Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension", Gastroenterology, 158, pp.1334~1345.e5 (2020)
84. Strowig T, "Inflammasomes in health and disease", Nature, 481, pp.278~286 (2012)
85. Szabo G, "Inflammasomes in liver diseases", J Hepatol, 57, pp.642~654 (2012)
86. Gross O, "The inflammasome : an integrated view", Immunol Rev, 243, pp.136~151 (2011)
87. Calvente CJ, "Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223", J Clin Invest, 129, pp.4091~4109 (2019)
88. Thapaliya S, "Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model", Dig Dis Sci, 59, pp.1197~1206 (2014)
89. Witek RP, "Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis", Hepatology, 50, pp.1421~1430 (2009)
90. Garcia-Tsao G, "Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension", J Hepatol, 72, pp.885~895 (2020)
91. Harrison SA, "A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis", J Hepatol, 72, pp.816~827 (2020)
92. Kim K, "Targeting of secretory proteins as a therapeutic strategy for treatment of nonalcoholic steatohepatitis(NASH)", Int J Mol Sci, 21, pp.2296~ (2020)
93. Yamamoto E, "Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition", Hypertension, 52, pp.573~580 (2008)
94. Wang PX, "Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates", Nat Med, 23, pp.439~449 (2017)
95. Sumida Y, "Current and future pharmacological therapies for NAFLD", NASH, 2018, pp.53, 362~376
96. Loomba R, "The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis : a randomized, phase 2 trial", Hepatology, 67, pp.549~559 (2018)
97. Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH : results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
98. Luedde T, "Deletion of NEMO", IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma, 2007, pp.11, 119~132
99. Luedde T, "Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia", reperfusion injury, 2005, pp.115, 849~859
100. Yang YM, "TNFα in liver fibrosis", Curr Pathobiol Rep, 3, pp.253~261 (2015)
101. Canbay A, "Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression", Hepatology, 38, pp.1188~1198 (2003)
102. Canbay A, "Apoptosis : the nexus of liver injury and fibrosis", Hepatology, 39, pp.273~278 (2004)
103. Noble PW, "Pirfenidone in patients with idiopathic pulmonary fibrosis(CAPACITY) : two randomised trials", Lancet, 377, pp.1760~1769 (2011)
104. King TE Jr, "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2083~2092 (2014)
105. Flores-Contreras L, "Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C", BMC Gastroenterol, 14, pp.131~ (2014)
106. Komiya C, "Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis", Sci Rep, 7, pp.44754~ (2017)
107. Poo JL, "Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis : PROMETEO study", Hepatol Int, 14, pp.817~827 (2020)
108. Kharitonenkov A, "FGF21 reloaded : challenges of a rapidly growing field", Trends Endocrinol Metab, 22, pp.81~86 (2011)
109. Charles ED, "Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study", Obesity(Silver Spring), 27, pp.41~49 (2019)
110. Itoh N, "FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases", Front Endocrinol(Lausanne), 5, pp.107~ (2014)
111. Sanyal A, "Pegbelfermin(BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with nonalcoholic steatohepatitis : a randomised, double-blind, placebocontrolled, phase 2a trial", Lancet, 392, pp.2705~2717 (2019)
112. Pose E, "Statins : old drugs as new therapy for liver diseases?", J Hepatol, 70, pp.194~202 (2019)
113. Dongiovanni P, "Statin use and non-alcoholic steatohepatitis in at risk individuals", J Hepatol, 63, pp.705~712 (2015)
114. Nascimbeni F, "Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease", BMJ Open Gastroenterol, 3, pp.e000075~ (2016)
115. Guaraldi G, "New drugs for NASH and HIV infection : great expectations for a great need", Hepatology, 71, pp.1831~1844 (2020)
116. Safadi R, "The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 12, pp.2085~2091.e1 (2014)
117. Sinha RA, "Nonalcoholic fatty liver disease and hypercholesterolemia : roles of thyroid hormones, metabolites, and agonists", Thyroid, 29, pp.1173~1191 (2019)
118. Zucchi R, "Thyroid hormone analogues : an update", Thyroid, 30, pp.1099~1105 (2020)
119. Loomba R, "LBP-20-VK2809, a novel liver-directed thyroid receptor beta agonist, significantly reduces liver fat with both low and high doses in patients with non-alcoholic fatty liver disease : a phase 2randomized, placebo-controlled trial", J Hepatol, 70, pp.e150~e151 (2019)
120. Harrison SA, "Resmetirom(MGL-3196)for the treatment of non-alcoholic steatohepatitis : a multicentre, randomised, double-blind, placebocontrolled, phase 2 trial", Lancet, 394, pp.2012~2024 (2019)
121. Kliewer SA, "Bile acids as hormones : the FXRFGF15", 19 pathway, 2015, pp.33, 327~331
122. Alisi A, "Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease", PLoS One, 8, pp.e67160~ (2013)
123. Wojcik M, "A decrease in fasting FGF19levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents", J Pediatr Endocrinol Metab, 25, pp.1089~1093 (2012)
124. Zhou M, "Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19", Cancer Res, 74, pp.3306~3316 (2014)
125. Zhou M, "Non-cell-autonomous activation of IL-6", STAT3 signaling mediates FGF19-driven hepatocarcinogenesis, 2017, pp.8, 15433~
126. Zhou M, "Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice", Hepatol Commun, 1, pp.1024~1042 (2017)
127. Harrison SA, "NGM282 for treatment of non-alcoholic steatohepatitis : a multicentre, randomised, double-blind, placebocontrolled, phase 2 trial", Lancet, 391, pp.1174~1185 (2018)
128. Schiff ER, "Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B", Clin Gastroenterol Hepatol, 9, pp.274~276 (2011)
129. Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
130. Akhtar E, "Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy : a meta-analysis", Liver Int, 35, pp.30~36 (2015)
131. Bachofner JA, "Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index", Liver Int, 37, pp.369~376 (2017)
132. Dolmazashvili E, "Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia : results of hepatology clinic HEPA experience", Eur J Gastroenterol Hepatol, 29, pp.1223~1230 (2017)
133. Borssén ÅD, "Histological improvement of liver fibrosis in welltreated patients with autoimmune hepatitis: a cohort study", Medicine (Baltimore), 96, pp.E7708~ (2017)
134. Corpechot C, "The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis", Hepatology, 32, pp.1196~1199 (2000)

관련 논문AI추천